Antisense Oligonucleotide
RO7434656 for IgA Nephropathy
Recruiting1 awardPhase 3
San Dimas, California
This trial is testing a new treatment that uses small genetic pieces to block harmful proteins in people with a specific kidney disease that isn't improving with current treatments. The treatment aims to stop the body from making proteins that make the disease worse.
Angiotensin Receptor Blocker and Endothelin Receptor Antagonist
Sparsentan for Proteinuric Kidney Disease
Recruiting1 awardPhase 2
Miami, Florida
This trial is testing sparsentan, a daily oral medication, in children with specific kidney diseases that cause high protein levels in urine. The goal is to see if it is safe and effective. Sparsentan helps by reducing protein leakage into the urine, which can protect the kidneys.
Popular Filters
Trials for Immunoglobulin A Nephropathy Patients
Endothelin Receptor Antagonist
Atrasentan for IgA Nephropathy
Recruiting0 awardsPhase 2
Chapel Hill, North Carolina
This trial is testing atrasentan, a medication for people with IgA nephropathy (IgAN) who are already on standard treatments. It works by blocking pathways that cause kidney damage, aiming to lower protein levels in the urine. Atrasentan has been previously tested for its effects on albuminuria reduction in patients with type 2 diabetes and nephropathy.
Biological Response Modifier
Atacicept for IgA Nephropathy
Recruiting1 awardPhase 3
Arvada, Colorado
This trial is testing a medication called atacicept for people with a kidney disease called IgA Nephropathy who still have too much protein in their urine despite other treatments. Atacicept works by calming the immune system to help reduce protein levels in the urine. The study will compare atacicept to see if it is effective and safe.
Monoclonal Antibodies
BION-1301 for Immunoglobulin A Nephropathy
Recruiting1 awardPhase 2
Northridge, California
This trial is testing BION-1301, a medicine that blocks a harmful protein, in adults with IgA nephropathy from a previous study. The medicine helps prevent kidney damage by stopping a specific protein from working.
Trials for IgAN Patients
Endothelin Receptor Antagonist
Atrasentan for IgA Nephropathy
Recruiting0 awardsPhase 2
Chapel Hill, North Carolina
This trial is testing atrasentan, a medication for people with IgA nephropathy (IgAN) who are already on standard treatments. It works by blocking pathways that cause kidney damage, aiming to lower protein levels in the urine. Atrasentan has been previously tested for its effects on albuminuria reduction in patients with type 2 diabetes and nephropathy.
Biological Response Modifier
Atacicept for IgA Nephropathy
Recruiting1 awardPhase 3
Arvada, Colorado
This trial is testing a medication called atacicept for people with a kidney disease called IgA Nephropathy who still have too much protein in their urine despite other treatments. Atacicept works by calming the immune system to help reduce protein levels in the urine. The study will compare atacicept to see if it is effective and safe.
Monoclonal Antibodies
BION-1301 for Immunoglobulin A Nephropathy
Recruiting1 awardPhase 2
Northridge, California
This trial is testing BION-1301, a medicine that blocks a harmful protein, in adults with IgA nephropathy from a previous study. The medicine helps prevent kidney damage by stopping a specific protein from working.
Phase 3 Trials
Biological Response Modifier
Atacicept for IgA Nephropathy
Recruiting1 awardPhase 3
Arvada, Colorado
This trial is testing a medication called atacicept for people with a kidney disease called IgA Nephropathy who still have too much protein in their urine despite other treatments. Atacicept works by calming the immune system to help reduce protein levels in the urine. The study will compare atacicept to see if it is effective and safe.
Endothelin Receptor Antagonist
Atrasentan for IgA Nephropathy
Recruiting1 awardPhase 3
Alhambra, California
This trial is testing a medication called atrasentan to help people with a kidney disease called IgA nephropathy. It aims to protect their kidneys by reducing protein in their urine. The study will compare atrasentan to another treatment over a few years. Atrasentan has been studied for its effects on reducing protein in urine and protecting kidney function in patients with diabetic nephropathy.
Trials With No Placebo
Monoclonal Antibodies
BION-1301 for Immunoglobulin A Nephropathy
Recruiting1 awardPhase 2
Northridge, California
This trial is testing BION-1301, a medicine that blocks a harmful protein, in adults with IgA nephropathy from a previous study. The medicine helps prevent kidney damage by stopping a specific protein from working.
Immunomodulator
Povetacicept for Autoimmune Kidney Diseases
Recruiting1 awardPhase 1 & 2
Phoenix, Arizona
This trial will assess if a drug (povetacicept) is safe & potentially beneficial in treating IgA nephropathy, membranous nephropathy & lupus nephritis. Participants receive drug every 4 weeks for 6 months, with the possibility of a 6-month extension.
Monoclonal Antibodies
Sibeprenlimab for IgA Nephropathy
Recruiting1 awardPhase 2 & 3
New York, New York
This trial is testing the safety and effectiveness of sibeprenlimab, an injectable medication, in patients with IgA Nephropathy who have been part of earlier studies. The medication likely helps manage symptoms or slow disease progression. Sibeprenlimab is being developed as a potential treatment for IgA nephropathy (IgAN).
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.